Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome

Matilda Holm, Sakari Joenväärä, Mayank Saraswat, Harri Mustonen, Tiialotta Tohmola, Ari Ristimäki, Risto Renkonen, Caj Haglund

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

Abstract Colorectal cancer (CRC) stands for 10% of the worldwide cancer burden and has recently become the second most common cause of cancer death. The 5-year survival rate depends mainly on stage at diagnosis. Mass spectrometric proteomic analysis is widely used to study the plasma proteome, which is complex and contains multitudes of proteins. In this study, we have used Ultra Performance Liquid Chromatography-Ultra Definition Mass Spectrometry (UPLC-UDMSE)-based proteomics to analyze plasma samples from 76 CRC patients. We identified several plasma proteins, such as CP, TVP23C, FETUB, and IGFBP3, of which altered levels led to significant differences in survival, as seen by Cox regression and Kaplan-Meier analysis. Additionally, during Cox regression analysis, samples were adjusted for age and/or tumor stage, enabling stringent analysis. These proteins, although in need of further validation, could be of use during patient follow-up, as their levels can non-invasively be measured from blood samples, and could be of use in predicting patient outcome. Several of these proteins additionally have roles in metabolism and inflammation, two processes central to the development and progression of cancer, further indicating their importance in cancer.
Alkuperäiskielienglanti
LehtiFASEB BioAdvances
Vuosikertan/a
Numeron/a
DOI - pysyväislinkit
TilaJulkaistu - 2 marraskuuta 2019
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 1182 Biokemia, solu- ja molekyylibiologia
  • 3122 Syöpätaudit

Lainaa tätä

@article{b5e1d9a7b3414029a3f04608c90ebc70,
title = "Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome",
abstract = "Abstract Colorectal cancer (CRC) stands for 10{\%} of the worldwide cancer burden and has recently become the second most common cause of cancer death. The 5-year survival rate depends mainly on stage at diagnosis. Mass spectrometric proteomic analysis is widely used to study the plasma proteome, which is complex and contains multitudes of proteins. In this study, we have used Ultra Performance Liquid Chromatography-Ultra Definition Mass Spectrometry (UPLC-UDMSE)-based proteomics to analyze plasma samples from 76 CRC patients. We identified several plasma proteins, such as CP, TVP23C, FETUB, and IGFBP3, of which altered levels led to significant differences in survival, as seen by Cox regression and Kaplan-Meier analysis. Additionally, during Cox regression analysis, samples were adjusted for age and/or tumor stage, enabling stringent analysis. These proteins, although in need of further validation, could be of use during patient follow-up, as their levels can non-invasively be measured from blood samples, and could be of use in predicting patient outcome. Several of these proteins additionally have roles in metabolism and inflammation, two processes central to the development and progression of cancer, further indicating their importance in cancer.",
keywords = "mass spectrometry, outcome, plasma proteome, proteomics, stage, 1182 Biochemistry, cell and molecular biology, 3122 Cancers",
author = "Matilda Holm and Sakari Joenv{\"a}{\"a}r{\"a} and Mayank Saraswat and Harri Mustonen and Tiialotta Tohmola and Ari Ristim{\"a}ki and Risto Renkonen and Caj Haglund",
year = "2019",
month = "11",
day = "2",
doi = "10.1096/fba.2019-00062",
language = "English",
volume = "n/a",
journal = "FASEB BioAdvances",
issn = "2573-9832",
publisher = "John Wiley & Sons, Ltd",
number = "n/a",

}

Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome. / Holm, Matilda; Joenväärä, Sakari; Saraswat, Mayank; Mustonen, Harri; Tohmola, Tiialotta; Ristimäki, Ari; Renkonen, Risto; Haglund, Caj.

julkaisussa: FASEB BioAdvances, Vuosikerta n/a, Nro n/a, 02.11.2019.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome

AU - Holm, Matilda

AU - Joenväärä, Sakari

AU - Saraswat, Mayank

AU - Mustonen, Harri

AU - Tohmola, Tiialotta

AU - Ristimäki, Ari

AU - Renkonen, Risto

AU - Haglund, Caj

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Abstract Colorectal cancer (CRC) stands for 10% of the worldwide cancer burden and has recently become the second most common cause of cancer death. The 5-year survival rate depends mainly on stage at diagnosis. Mass spectrometric proteomic analysis is widely used to study the plasma proteome, which is complex and contains multitudes of proteins. In this study, we have used Ultra Performance Liquid Chromatography-Ultra Definition Mass Spectrometry (UPLC-UDMSE)-based proteomics to analyze plasma samples from 76 CRC patients. We identified several plasma proteins, such as CP, TVP23C, FETUB, and IGFBP3, of which altered levels led to significant differences in survival, as seen by Cox regression and Kaplan-Meier analysis. Additionally, during Cox regression analysis, samples were adjusted for age and/or tumor stage, enabling stringent analysis. These proteins, although in need of further validation, could be of use during patient follow-up, as their levels can non-invasively be measured from blood samples, and could be of use in predicting patient outcome. Several of these proteins additionally have roles in metabolism and inflammation, two processes central to the development and progression of cancer, further indicating their importance in cancer.

AB - Abstract Colorectal cancer (CRC) stands for 10% of the worldwide cancer burden and has recently become the second most common cause of cancer death. The 5-year survival rate depends mainly on stage at diagnosis. Mass spectrometric proteomic analysis is widely used to study the plasma proteome, which is complex and contains multitudes of proteins. In this study, we have used Ultra Performance Liquid Chromatography-Ultra Definition Mass Spectrometry (UPLC-UDMSE)-based proteomics to analyze plasma samples from 76 CRC patients. We identified several plasma proteins, such as CP, TVP23C, FETUB, and IGFBP3, of which altered levels led to significant differences in survival, as seen by Cox regression and Kaplan-Meier analysis. Additionally, during Cox regression analysis, samples were adjusted for age and/or tumor stage, enabling stringent analysis. These proteins, although in need of further validation, could be of use during patient follow-up, as their levels can non-invasively be measured from blood samples, and could be of use in predicting patient outcome. Several of these proteins additionally have roles in metabolism and inflammation, two processes central to the development and progression of cancer, further indicating their importance in cancer.

KW - mass spectrometry

KW - outcome

KW - plasma proteome

KW - proteomics

KW - stage

KW - 1182 Biochemistry, cell and molecular biology

KW - 3122 Cancers

U2 - 10.1096/fba.2019-00062

DO - 10.1096/fba.2019-00062

M3 - Article

VL - n/a

JO - FASEB BioAdvances

JF - FASEB BioAdvances

SN - 2573-9832

IS - n/a

ER -